Technical Analysis for GRCL - Gracell Biotechnologies Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 14.65 | 5.47% | 0.76 |
GRCL closed up 2.89 percent on Monday, April 12, 2021, on 50 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Down | Up |
Historical GRCL trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
1,2,3 Retracement Bearish | Bearish Swing Setup | 5.47% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 5.47% | |
Narrow Range Bar | Range Contraction | 5.47% | |
NR7 | Range Contraction | 5.47% | |
Inside Day | Range Contraction | 5.47% | |
Wide Bands | Range Expansion | 5.47% | |
Oversold Stochastic | Weakness | 5.47% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | 8.52% | |
180 Bearish Setup | Bearish Swing Setup | 8.52% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 8.52% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Up 5% | about 3 hours ago |
Rose Above Previous Day's High | about 4 hours ago |
Outside Day | about 4 hours ago |
Up 3% | about 4 hours ago |
Up 2% | about 4 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Solid Tumors Immune System Health Sciences Lymphoma Cancer Immunotherapy Gene Therapy Chimeric Antigen Receptor T Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Solid Tumors Immune System Health Sciences Lymphoma Cancer Immunotherapy Gene Therapy Chimeric Antigen Receptor T Cell
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 33.6999 |
52 Week Low | 12.3 |
Average Volume | 104,491 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 22.35 |
20-Day Moving Average | 18.00 |
10-Day Moving Average | 14.01 |
Average True Range | 1.87 |
ADX | 31.0 |
+DI | 15.51 |
-DI | 27.24 |
Chandelier Exit (Long, 3 ATRs ) | 19.08 |
Chandelier Exit (Short, 3 ATRs ) | 17.90 |
Upper Bollinger Band | 26.67 |
Lower Bollinger Band | 9.34 |
Percent B (%b) | 0.26 |
BandWidth | 96.23 |
MACD Line | -2.66 |
MACD Signal Line | -2.38 |
MACD Histogram | -0.2776 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 15.26 | ||||
Resistance 3 (R3) | 15.26 | 14.82 | 15.03 | ||
Resistance 2 (R2) | 14.82 | 14.47 | 14.81 | 14.95 | |
Resistance 1 (R1) | 14.35 | 14.25 | 14.13 | 14.35 | 14.88 |
Pivot Point | 13.91 | 13.91 | 13.80 | 13.90 | 13.91 |
Support 1 (S1) | 13.44 | 13.56 | 13.22 | 13.44 | 12.90 |
Support 2 (S2) | 13.00 | 13.34 | 12.99 | 12.83 | |
Support 3 (S3) | 12.53 | 13.00 | 12.75 | ||
Support 4 (S4) | 12.53 |